Best Hospitals for Patent Ductus Arteriosus (PDA) Device Closure in Dubai, UAE

The total cost of transcatheter PDA Device Closure (catheterization laboratory fee, device cost, anesthesia, hospital stay of 1–3 days, standard medications, and post-procedure echocardiography) ranges from approximately USD 2,500 to USD 5,000 in India at JCI- and NABH-accredited centers such as Narayana Health, Apollo Hospitals, Amrita Institute of Medical Sciences, and Fortis Healthcare. The same procedure at JCI- and DHA/DOH-accredited hospitals in Dubai or Abu Dhabi (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, American Hospital Dubai, Sheikh Khalifa Medical City) ranges from approximately USD 7,000 to USD 14,000 — reflecting premium infrastructure, higher overheads, and device import costs in the UAE market. India's price advantage of 40–60% does not imply inferior outcomes: India's top congenital cardiac centers perform thousands of PDA closures annually, and clinical success rates are equivalent to leading Western institutions. Additional costs to factor in include the device implant itself (ADO-I or ADO-II devices cost USD 800–2,500 depending on size and supplier; this is usually included in the Indian package quote but should be confirmed), international travel, accommodation, and GAF Healthcare's coordination fee. GAF Healthcare provides a fully itemized, no-hidden-fee treatment quote within 48–72 hours of receiving the patient's medical records.

For the vast majority of transcatheter PDA Device Closure cases in children and adults, the treating cardiologist will assess fitness to fly based on three criteria: (1) clinical stability with no procedural complications, (2) echocardiographic confirmation of satisfactory device position with no hemodynamically significant residual shunt, and (3) intact vascular access site healing. For short-haul flights (under 3–4 hours), most patients are cleared to fly at Day 7–10 post-procedure. For long-haul intercontinental flights (5 hours or more — common for patients traveling from Africa, Europe, North America, or Central Asia), we recommend a minimum stay of 14–21 days to allow a repeat echocardiogram at Day 14, confirming device stability and absence of late complications such as hemolysis, device migration, or new arrhythmia. Surgical ligation cases (VATS or open thoracotomy) require a slightly longer observation period of 14–21 days before any air travel, due to the thoracic incision and the small risk of delayed pneumothorax or chylothorax. GAF Healthcare's treating cardiologist issues a formal aviation medical clearance letter with specific recommendations tailored to the patient's anatomy, device used, and recovery trajectory. This letter is essential documentation for airline boarding and international customs if carrying medical device identification cards.

Transcatheter PDA Device Closure using contemporary nitinol occluder devices (Amplatzer Duct Occluder I and II, Occlutech Duct Occluder, Piccolo Occluder) achieves a procedural success rate of 97–99% in high-volume congenital cardiac catheterization centers — defined as complete device deployment with satisfactory positioning and no immediate major complication requiring surgical conversion. Complete occlusion (no residual shunt on color Doppler echocardiography) is achieved in approximately 85–90% of patients at 24 hours, rising to 95–98% by 6 months as the device becomes fully endothelialized and any trivial residual shunting seals spontaneously. Surgical PDA ligation (VATS or open thoracotomy) has a closure rate approaching 100% but carries slightly higher complication rates (recurrent laryngeal nerve injury, chylothorax) compared to transcatheter approaches in experienced hands. The long-term prognosis after successful closure is excellent: left ventricular dimensions normalize within 3–6 months, pulmonary artery pressures reduce in the majority of patients with non-severe pre-operative PAH, and patients typically achieve full physical activity without restriction. Patients presenting with established severe pulmonary arterial hypertension (Eisenmenger syndrome, PVRI ≥ 8 Wood units) are not candidates for closure, as sealing the duct in this setting precipitates acute right ventricular failure; these patients are managed with targeted PAH pharmacotherapy (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogs). GAF Healthcare's partner centers perform individualized hemodynamic assessment — including vasoreactivity testing with inhaled nitric oxide — to ensure that only patients who will genuinely benefit from closure undergo the procedure.